[April 20, 2015] |
|
Rosetta Genomics Announces Data Published in Leukemia Research
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of
microRNA-based molecular and other diagnostics, announces that data
highlighting its microRNA platform technology was published in Leukemia
Research in an article entitled, "microRNA signature is indicative
of long term prognosis in diffuse large B cell lymphoma." The article
can be accessed online at www.lrjournal.com.
The study compared microRNA (miR) expression between patients with
diffuse large B-cell lymphoma (DLBCL) who had a poor prognosis with
those who had a favorable prognosis. DLBCL accounts for 30-40% of all
adult non-Hodgkin's lymphomas and is heterogeneous in terms of clinical
features and prognosis.
The study group included 83 patients with DLBCL. miR signature from
tissue biopsies was compared between patients who relapsed within nine
months from commencement of treatment (defined as poor prognosis, n=43)
and those with disease-free survival of at least five years (defined as
good prognosis, n=40). RNA was analyzed using Rosetta's custom
microarrays. Quantitative real-time polymerase chain reaction (qRT-PCR (News - Alert))
was used for technical validation of microarray results. Eight miRs were
found to be differently expressed between the two prognostic groups.
In the poor prognosis group, hsa-miR-17-5p, hsa-miR-19b-3p,
hsa-miR-20a-5p and hsa-miR-106a-5p were found to be up-regulated, while
hsa-miR-150-5p, hsa-miR-342-3p, hsa-miR-181a-5p and hsa-miR-140-3p were
found to be down-regulated, compared with the good prognosis group.
"Our data are in agreement with previous findings showing that miR
signature is predictive of prognosis for patients with DLBCL, although
with different miRs achieving statistical significance," noted the
study's lead author, Prof. Meir Lahav, M.D., Institute of Hematology,
Davidoff Centre, Rabin Medical Centre, Beilinson Hospital, Petah Tikva,
Israel and Sackler School of Medicine, Tel Aviv University, Tel Aviv,
Israel.
"These are exciting data as they illustrte our proprietary platform's
ability to identify microRNA signatures in hematologic malignancies that
can differentiate poor and favorable prognostic groups," noted Kenneth
A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
"Importantly, these data complement our broader commitment to expand our
commercial offerings and clinical pipeline in oncology diagnostics."
About Rosetta Cancer Testing Services Rosetta Cancer Tests
are a series of microRNA-based diagnostic testing services offered by
Rosetta Genomics. The Rosetta Cancer Origin Test™ can
accurately identify the primary tumor type in primary and metastatic
cancer including cancer of unknown or uncertain primary (CUP). The
Rosetta Lung Cancer Test™ accurately identifies the four main
subtypes of lung cancer using small amounts of tumor cells. The Rosetta
Kidney Cancer Test™ accurately classifies the four most
common kidney tumors: clear cell renal cell carcinoma (RCC), papillary
RCC, chromophobe RCC and oncocytoma. Rosetta's assays are designed to
provide objective diagnostic data. In the U.S. alone, Rosetta Genomics
estimates that 200,000 patients a year may benefit from the Rosetta
Cancer Origin Test™, 62,000 from the Rosetta Kidney Cancer
Test™ and 222,000 patients from the Rosetta Lung Cancer Test™.
The Company's assays are offered directly by Rosetta Genomics in the
U.S., and through distributors around the world. In addition to its
proprietary products, the Company markets the Rosetta Genomics PGxOne™
and EGFR and KRAS tests for Admera Health. With the recent
acquisition of PersonalizeDx, the company now offers a broader menu of
molecular and other assays for lung, bladder, prostate and breast cancer
patients. For more information, please visit www.rosettagenomics.com.
Parties interested in ordering any of these tests can contact Rosetta
Genomics at (215) 382-9000 ext. 309.
About Rosetta Genomics Rosetta develops and commercializes a
full range of microRNA-based molecular diagnostics. Founded in 2000,
Rosetta's integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building on
its strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the
development and commercialization of a full range of microRNA-based
diagnostic tools. PersonalizeDx's core FISH, IHC and PCR-based testing
capabilities and partnerships in oncology and urology provide additional
content and platforms that complement the Rosetta offerings. Rosetta's
and PersonalizeDx's cancer testing services are commercially available
through the Philadelphia, PA- and Lake Forest, CA (News - Alert)-based CAP-accredited,
CLIA-certified labs, respectively.
Forward-Looking Statement Disclaimer Various statements in
this release concerning Rosetta's future expectations, plans and
prospects, including without limitation, statements relating to
Rosetta's proprietary platform's ability to identify microRNA signatures
in hematologic malignancies that can differentiate poor and favorable
prognostic groups and the extent to which this data complements the
possibilities for Rosetta's expanding its commercial offerings and/or
clinical pipeline, constitute forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by these forward-looking statements as a result of
various important factors, including those risks more fully discussed in
the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for
the year ended December 31, 2014 as filed with the SEC (News - Alert). In addition, any
forward-looking statements represent Rosetta's views only as of the date
of this release and should not be relied upon as representing its views
as of any subsequent date. Rosetta does not assume any obligation to
update any forward-looking statements unless required by law.
[ Back To TMCnet.com's Homepage ]
|